



Symbio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

March 26, 2008

Symbio Pharmaceuticals Limited.

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

Symbio Pharmaceuticals Signs License Agreements with Yuhan Yang Haeng and InnoPharmax for South Korea and Taiwan Markets

TAIPEI, Taiwan, and SEOUL, Korea--March 26--Symbio Pharmaceuticals (Shimbashi, Minato-ku, Tokyo), which is expanding in Japan and the Asia Pacific region, has signed a sub-licensing agreement with Yuhan Yang Haeng, a Korean pharmaceutical company, and InnoPharmax, a Taiwanese bio-venture company, as part of expansion plans in Asia Pacific for two drug candidates it currently has under development in Japan. Establishing a close strategic partnership with companies in Taiwan and Korea is a key element of Symbio's Asia Pacific Rim initiative in developing and delivering effective therapies to Asian patients in cancer and hematology outside of Japan.

Symbio Pharmaceuticals signed a licensing agreement with Yuhan Yang Haeng (49-6, Taebang-dong, Dongjak-gu, Seoul, South Korea) on March 24, 2008 for an antiemetic patch, SyB D-0701 (transdermal patch formulation of granisetron), which it in-licensed from Abeille Pharmaceuticals, Inc., a Princeton, New Jersey-based company and the original licensor of SyB-0701. Symbio has completed a Phase 1 study for this transdermal patch in Japan. Under this agreement, Yuhan Yang Haeng will proceed with development and commercialization plans in South Korea, with launch scheduled for 2010. Symbio Pharmaceuticals signed license agreements with InnoPharmax (No. 52, Lane 188, Rueiguang Rd., Taipei, Taiwan) on March 23, 2008 for both SyB D-0701 and SyB L-0501 (bendamustine hydrochloride - a neoplastic agent in-licensed from Astellas Pharma GmbH); based on positive Phase 1 data, Symbio initiated a Phase 2 clinical study in Japan in December 2007 with rituximab-refractory patients having low-grade indolent non-Hodgkin's lymphoma (NHL). InnoPharmax will proceed with plans to develop and launch both drugs in Taiwan. Under all three agreements, Symbio will receive double-digit royalties in addition to upfront and milestone payments.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan, with the corporate mission of addressing underserved therapeutic areas having high medical need in Japan, Korea, Taiwan and other Asia Pacific Rim countries. SymBio's main focus lies in the development of drugs within three therapeutic areas: oncology, hematology and autoimmune disease. Through its proprietary in-house search and evaluation process and experienced management team having strong development expertise in biopharmaceuticals, SymBio is able to adopt unique strategies in the development of drug candidates in order to bring much-needed therapies to market as nimbly as possible.

For further information, please contact:

SymBio Pharmaceuticals Limited.

Osamu Ogawa,

Board Director, Senior Corporate Officer,

Senior Director, Research & Development

Tel: +081(0)3 5472 1123

E-mail: Please send your inquiry through "INQUIRY" in our homepage

URL:<http://www.symbiosis.co.jp>